Understanding the EFFECT and sub-EFFECT Studies: What Do They Mean for People Living with HIV?

By

In many parts of Africa, including South Africa and Tanzania, some people living with HIV still get very sick because their immune system is weak. One serious illness they can get is cryptococcal meningitis, a deadly infection that affects the brain. It is caused by a fungus called Cryptococcus.

Luckily, there's a test that can find the infection early, before it spreads to the brain. This test looks for a warning sign in the blood called CrAg (cryptococcal antigen). If the test is positive, it means the person might be at risk of developing meningitis.

Two important studies, called EFFECT and sub-EFFECT, are helping us learn the best way to protect people who test CrAg-positive.

What is the EFFECT Study?

The EFFECT study is testing a new way to treat people who are CrAg-positive but do not yet have meningitis. These people feel fine, but their blood test shows they could get sick soon if not treated.

Right now, many are given a medicine called fluconazole. But studies show that some people still die even after taking fluconazole alone.

The EFFECT study wants to answer this question:
“What if we add another medicine called flucytosine to the treatment? Can it save more lives?”

In this study, people are given either:

  • Fluconazole only (the current treatment)
  • Fluconazole plus Flucytosine (the new option)

All patients get a lumbar puncture to check if the infection has already reached the brain. If the test shows the infection is only in the blood, they can join the EFFECT study.

To be eligible for EFFECT, participants must:

  • Be HIV-positive
  • Have a CD4 count below 100
  • Test CrAg-positive in blood
  • Have no symptoms or signs of meningitis
  • Have a negative lumbar puncture

What is the sub-EFFECT Study?

Some people who feel fine still have the infection in their brain, even though they have no symptoms. This is called subclinical meningitis. You can’t see or feel it, but it is there.

These people are not allowed to join the EFFECT study because they already have the infection in the brain. Instead, they get the usual hospital treatment for meningitis, and doctors keep track of their progress in a separate study called sub-EFFECT.

In simple words:
🧍‍If you test CrAg-positive and your brain is not yet infected, you may join EFFECT
🧍‍If your brain is already infected (even without symptoms), you go into sub-EFFECT

Why Does This Matter?

These studies are helping doctors and health workers understand:

  • Which treatment works best to stop the infection early
  • How to reduce deaths from cryptococcal meningitis
  • What to do when a person has no symptoms but already has infection in the brain

With this knowledge, health systems can offer better care, save more lives, and prevent suffering for people living with HIV.

Let us continue supporting efforts like EFFECT and sub-EFFECT. Together, we can make sure that no one dies from preventable fungal infections.

Welcome to my blog dedicated to community engagement in HIV research. Here, we delve deep into the latest advancements and discussions surrounding HIV cure, treatment, prevention, and management of advanced HIV infection. My goal is to bridge the gap between complex scientific research and community understanding, ensuring that knowledge is accessible and actionable. Join me as I explore these critical topics, engage with community insights, and contribute to the ongoing fight against HIV.

Comments

Post a Comment

Popular posts from this blog

Aging with HIV in Botswana: Time to Update Our Treatment Guidelines

By
A New Face of Botswana’s HIV Epidemic As an HIV activist, I have witnessed a profound shift in our epidemic’s demographics. Two decades ago, the focus was on keeping people alive. Today, thanks to widespread antiretroviral therapy (ART), many of those same people are alive into their 50s, 60s, and beyond. In fact, Botswana’s HIV population is graying rapidly. By some estimates, over 50% of people living with HIV in Botswana are now over 40 years old, making older adults the new face of our country’s HIV community. This is a testament to our success in expanding treatment, but it also presents urgent new challenges. While ART has extended life expectancy, additional years of life are not necessarily spent in good health. Many older PLHIV are surviving, but not thriving. They struggle with chronic pain, fatigue, heart disease, or depression. Such stories underscore a hard truth: we have won on longevity, but we are lagging on quality of life. Medical complications, multimorbidities, ...
Read more

HIV Prevention Research in a Time of Scarcity: Why Health Economics Must Lead the Way

By
What is Health Economics? Health economics is a field of study that examines how health resources are allocated, used, and financed. It helps decision-makers understand the trade-offs involved in investing in different health interventions by analysing their costs, benefits, and overall impact on population health. Through tools such as cost-effectiveness analysis and budget impact modelling, health economics supports evidence-based decisions that aim to maximise health outcomes with limited resources. In HIV prevention, this means ensuring that every intervention, from new biomedical tools to health service delivery, delivers real value for money and is accessible to the people who need it most. Why Health Economics Literacy Matters for HIV Advocates As an AVAC Clinical Trials Design Academy member and advocate for HIV prevention, developing health economics literacy is vital. It empowers advocates to engage meaningfully in decision-making spaces, to interrogate the value and feasi...
Read more

Highlights from the HIV Cure Pre-Conference at AIDS 2024

By
The 2024 HIV Cure Pre-Conference at AIDS 2024, held today, 21 July 2024, in Munich, was a pivotal event that brought together leading experts and researchers from around the globe to discuss the latest advancements, ongoing challenges, and the future direction of HIV cure research. This pre-conference served as a critical platform for sharing insights into the scientific, structural, and global coordination efforts needed to push forward the ambitious goal of achieving a functional or complete cure for HIV. Keynote Presentation by Deborah Persaud The event began with a powerful keynote address by Dr. Deborah Persaud, who is recognized for her groundbreaking work in pediatric HIV cure research. Dr Persaud provided a comprehensive overview of the current landscape of HIV cure research, particularly focusing on Latency-Reversing Agents (LRAs) in clinical trials. She presented a detailed systematic review that highlighted the need for meticulously designed studies to determine the precise ...
Read more